TP53 and uterine cervix carcinoma in situ: p53 positivity was seen in 51% (51/100) cases, which increased from CIN I to CIN II (CIN I – 47.22%, CIN II – 61.11%) and slightly decreased in CIN III (54.05%) (Figure 3).